Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Durata

- PMLiVE

Sanofi patent case win holds off generic rivals for key cancer drug

Boosts hope of increasing future sales

- PMLiVE

Peter Kelly named managing director of Accord Healthcare UK

He was previously commercial director at Actavis UK

- PMLiVE

Lilly wins on appeal in Alimta vitamin regimen dispute

UK Supreme Court rules in its favour over Actavis

- PMLiVE

Teva sells UK and Ireland assets to Intas Pharma for £603m

Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

- PMLiVE

UK court backs Actavis in dispute over Lilly’s Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

- PMLiVE

UK government fines GSK over ‘pay-for-delay’ deals

Merck KGaA and Actavis also fined for their involvement

- PMLiVE

Horizon launches $3bn hostile bid for Depomed

Horizon wants to add Depomed’s pain therapies and CNS drugs to its products

- PMLiVE

Teva planning fresh offer for Mylan, say sources

Israeli firm has already made multiple informal bids

- PMLiVE

Receptos rejected AZ takeover bid, say sources

Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva

- PMLiVE

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

- PMLiVE

FDA approves two new IBS medicines

US regulator gives the nod to Actavis’ and Salix’ bowel drugs

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links